Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Southern Africa has seen significant growth in recent years due to several factors.
Customer preferences: Customers in Southern Africa have shown a preference for innovative and effective oncology drugs. They are increasingly willing to pay for the latest treatments that have been proven to be effective in treating cancer. Patients are also seeking drugs with fewer side effects and a higher success rate.
Trends in the market: One of the major trends in the Oncology Drugs market in Southern Africa is the increasing prevalence of cancer in the region. This has led to a growing demand for oncology drugs, particularly in the treatment of breast, lung, and prostate cancer. Another trend is the increasing use of targeted therapies, which are more effective in treating cancer and have fewer side effects than traditional chemotherapy.
Local special circumstances: Southern Africa faces unique challenges in the Oncology Drugs market. One of the major challenges is the high cost of oncology drugs, which limits access to treatment for many patients. Additionally, there is a lack of infrastructure and trained personnel in many areas, which makes it difficult to provide adequate care for cancer patients.
Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the Oncology Drugs market in Southern Africa. These include the increasing prevalence of cancer in the region, the growing middle class, and the increasing availability of healthcare services. Additionally, the region has seen significant investment in healthcare infrastructure in recent years, which has helped to improve access to treatment for cancer patients.In conclusion, the Oncology Drugs market in Southern Africa is growing rapidly due to increasing customer demand for innovative and effective treatments, the rising prevalence of cancer in the region, and the improving healthcare infrastructure. However, the high cost of oncology drugs and the lack of infrastructure and trained personnel in many areas remain significant challenges that need to be addressed in order to ensure that all patients have access to adequate care.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
